Prediction of Pharmacological Substances and Mechanism of Action of Xiaoyao San in the Treatment of Chronic Hepatitis B Complicated with Metabolic Related Fatty Liver Disease Based on Network Pharmacology
Objective To predict and analyze the pharmacological components and mechanism of action of Xiaoyao San in the treatment of chronic hepatitis B(CHB)combined with metabolic associated fatty liver disease(MAFLD)using network pharmacology methods,providing ideas and directions for further experimental verification research.Methods TCMSP was used to obtain the main chemical components and active ingredients of traditional Chinese medicine in Xiaoyao San,and the protein targets of the compounds were standardized in the Uniprot protein database.Retrieve the main targets of CHB and MAFLD from the GeneCards database,draw a Venn diagram using Venn analysis tools,and obtain the intersection targets of the three.Subsequently,a PPI network model was constructed in the STRING 11.5 database and CytoScape 3.9.1.Perform enrichment analysis on potential targets using the Metascape data platform.Results The core active ingredients of Xiaoyao San in the intervention of CHB combined with MAFLD are compounds such as kaempferol,quercetin,luteolin,and β-sitosterol.The core targets include RELA,MAPK1,MAPK3,AKT1,IL6,and other targets.Xiaoyao San intervenes in the biological pathways of CHB combined with MAFLD,mainly acting on signaling pathways such as Relaxin,IL-17,HIF-1,etc.It has anti-inflammatory,antioxidant,and collagen deposition inhibiting effects,thereby reducing liver inflammation damage and improving liver fibrosis.Conclusion Xiaoyao San may act on the expression of target proteins such as RELA,MAPK1,MAPK3,AKT1,and IL6 through signaling pathways such as Relaxin,IL-17,and HIF-1 in the treatment of CHB combined with MAFLD.It has anti-inflammatory,antioxidant,and collagen deposition inhibiting effects,thereby reducing liver inflammation and improving liver fibrosis.
Chronic hepatitis BMetabolic related fatty liver diseaseNetwork pharmacologyXiaoyao San
万方数据
维普
